Tislelizumab (Tuoyi)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tislelizumab (Tuoyi), covering 2026-02-18 to 2026-02-18. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma [Phase 2]